Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre

Anuja Desai a,*, Parth Desai b, Jigar Mehta c, Wasimahmed Sachora d, Neeraj Bharti e, Tushar Patel f, Kalpesh Sukhwani g, Ankita Jain h, Dipesh Sorathiya i, Vivek Nanda j, Parin Mehta k, Adit Desai l

a Department of Ophthalmology, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
b Department of Critical Care Medicine, Kusum Dhirajal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
c Department of General Medicine, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
d Department of Pulmonary Medicine, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
e Department of Infectious Disease, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
f Department of Obstetrics and Gynecology, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
g Department of In-vitro Fertilization, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
h Department of Emergency Medicine, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
i Department of Ophthalmology, Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India
j Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India

ARTICLE INFO

Article history:
Received 6 September 2021
Revised 12 October 2021
Accepted 14 October 2021

KEYWORDS:
COVID-19 vaccination
SARS-CoV-2 infection
ChAdOx1 nCoV-19 vaccine
vaccine hesitancy

ABSTRACT

Objective: To comparatively evaluate ICU requirement, length of stay, and mortality between single-dose vaccinated and non-vaccinated hospitalized COVID-19 patients.

Design: A retrospective observational study was carried out in a tertiary care hospital in western India, from April 1 to June 30, 2021.

Results: Of the 569 patients who fulfilled the eligibility criteria and were enrolled in the study, 137 (24.08%) patients had received a single dose of ChAdOx1 nCoV-19 vaccine, while 432 (75.92%) patients had not received any form of vaccination. The overall length of stay in hospital was similar for both groups; however, a significant difference was seen in length of stay in the ward and in the ICU. Vaccinated patients were admitted to the ward for 6.21 ± 3.204 days, while non-vaccinated patients were admitted for 5.56 ± 4.55 days (p < 0.001). The mean length of ICU stay for the 21 vaccinated patients requiring intensive care was 4.47 ± 2.3 days, while that for the 145 non-vaccinated patients was 6.29 ± 2.19 days (p < 0.001). Mortality was observed in four patients in the vaccinated group and in 95 patients in the non-vaccinated group.

Conclusion: A single dose of ChAdOx1 nCoV-19 vaccine was associated with a significantly lower severity of SARS-CoV-2 infection compared with no vaccination.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Corresponding author: Anuja Desai, MS, FMRF (cornea), Kusum Dhira Jal Hospital, Vaishnodevi Circle, SG Road, Ahmedabad, 382421, Gujarat, India, +91-9925531512.
E-mail addresses: dranuja@kdhospital.co.in (A. Desai), parth@kdhospital.co.in (P. Desai), drjigar74@yahoo.com (J. Mehta), wasimsachora@yahoo.com (W. Sachora), neerajbharti2001@gmail.com (N. Bharti), drtusharpate@yahoo.com (T. Patel), kalpesh.sukhwani@gmail.com (K. Sukhwani), drankitajain@yahoo.com (A. Jain), drdipeshsorathiya@gmail.com (D. Sorathiya), dr.viveknanda@gmail.com (V. Nanda), parinmehta23@gmail.com (P. Mehta), adit@kdhospital.co.in (A. Desai).

https://doi.org/10.1016/j.ijid.2021.10.032
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

On March 11, 2020, WHO declared COVID-19 to be a pandemic [World Health Organization, 2020]. Most of countries have since faced significant challenges in combating this disease. By June 2021, the cumulative number of cases reported globally had exceeded 180 million, and the number of global deaths had reached almost 4 million across 216 countries.

India has been among the highest-ranked countries in terms of sharp surges in identified cases, as well as death rates. During the first wave of the pandemic, the rate of SARS-CoV-2 infection was somewhat controlled by the nationwide lockdown imposed by the Indian Government in March, 2020 [Singh and Adhikari, 2020]. However, due to an increase in community transmission of the virus, the 7-day average of daily cases in India reached 93,617 on September 16, 2020, which at that point was the highest recorded so far [Pujari and Shekatkar, 2020].

The global vaccination development efforts by leading pharmaceutical companies have shown positive outcomes in terms of providing immunity, as well as decreasing the severity of the disease with up to 94% efficacy [World Health Organization COVID tracker, 2020]. The Government of India has approved emergency authorization for two of the eight vaccine candidates currently under clinical trials. First is the non-replicating chimpanzee adenovirus vaccine vector ChAdOx1, manufactured by the Serum Institute of India in collaboration with the University of Oxford and AstraZeneca, under the trade name Covishield™ [Voysey et al., 2021]. The second is the inactivated-virus vaccine BBV152, developed by Bharat Biotech International under the trade name Covaxin™ [Ella et al., 2021a]. At the height of the crisis, India gave restricted approval to the Russian vaccine SPUTNIK-V [ICMR New Delhi, 2021].

Despite India’s extensive vaccination campaign, only a fraction of the population has been vaccinated due to the country very large population [Bagchi, 2021 and Ranjan et al., 2021]. Towards the end of June 2021, 370 million doses had been administered, resulting in roughly 5% of the total population being fully vaccinated and 22% receiving at least a single dose. Of these, 321.4 million doses of Covishield™ and 45.47 million doses of Covaxin™ had been administered [ICMR New Delhi, 2021].

On April 26, 2021, India saw the highest daily tally of new SARS-CoV-2 infections ever recorded in the world (360,960), taking its pandemic total to 16 million cases — second only to the US — and more than 200,000 deaths. The devastating second wave came a year after the country imposed one of the most rigid lockdown restrictions in the world, and just 3 months after the health ministry declared that infections and mortality were at an all-time low [Thiagarajan, 2021].

The second wave of COVID-19 in India has had severe consequences in the form of spiraling cases, reduced supplies of essential treatments, and increased deaths — particularly in the young population. Studies have identified various circulating double- and triple-mutant strains of the original B.1.617 lineage of SARS-CoV-2, known as Delta AY.1 and Delta AY.2, across different regions of India, which are more pathogenic than the initial strains [Asrani et al., 2021 and Lancet, 2021]. The Delta variant has been reported to be 60% more transmissible than the Alpha variant (B.1.1.7), and WHO has designated the Delta variant as a variant of concern (VOC) [Kale et al., 2021].

The government of India has imposed multiple measures to reduce the spread and flatten the curve. The ‘test-track-treat’ protocol has been implemented since April 2021 [Ministry of Home Affairs, 2021]. This includes RT-PCR testing, isolating/quarantining positive cases, tracing all possible contacts within 72 hours, imposing curfews in major cities, containment zoning in high-volume areas, bans on religious/political gatherings, travel restrictions, and prioritizing vaccinations for certain population groups.

Developing an infection after vaccination is known as a ‘breakthrough infection’. So far, 2–4 breakthrough infections per 10,000 people have occurred, which is a very low number [Tyagi et al., 2021]. Patients infected with SARS-CoV-2 in the first wave were predominantly older than 60 years, and those with comorbid conditions were at increased risk of death. However, surprisingly, younger adults appear to be prone to infection during this second wave, and many patients have died at a young age, including those aged 25–50 years [Jain et al., 2021].

Our study aimed to estimate the real-life impact of a single dose of ChAdOx1 nCoV-19 vaccine on hospitalized patients infected with SARS-CoV-2. Our primary outcome was to determine the efficacy of a single vaccine dose in reducing the severity of SARS-CoV-2 infection. It is hoped that our results will have some impact in decreasing vaccine hesitancy in the population and encouraging more people to become vaccinated, so that maximum immunity can be achieved.

Materials and methods

Study design

This was a retrospective, single-centre, descriptive observational study based on secondary clinical data analysis of patients admitted to a tertiary COVID care centre (CCC) from April 1 to June 30, 2021 in western India. The subjects were categorized into two cohorts based on their ChAdOx1 nCoV-19 vaccination status. The protocol, performa, case record form, and informed consent form were reviewed by the Institutional Ethics Committee (IEC). The study was initiated after receiving written approval from the IEC and written informed consent of participants in vernacular language. Confidentiality of all the data was maintained.

Study participants

Consenting patients aged 18 years and above, with symptomatic SARS-CoV-2 infection and a positive polymerase chain reaction, were considered eligible; these accounted for about 94% of total admissions. Patients who had received a single dose of ChAdOx1 nCoV-19 vaccine were placed in one group, while those who had not received any vaccine were in the control group. Patients vaccinated with any vaccine other than those defined in the inclusion criteria were excluded from the study. Patients vaccinated with both doses of ChAdOx1 nCoV-19 were also excluded because the sample size for that cohort was very low. The criteria for admission to the ward and the ICU for the SARS-CoV-2 patients were predetermined, based on presenting symptoms and clinical signs.

Data collection

Demographic data, such as age and gender, were recorded on the case record form. Next, the following data were recorded: date of admission; date of positive RT-PCR test, fresh infection, or re-infection; vaccination details, including date of vaccination; length of stay in hospital; duration of stay in ward and/or intensive care unit; and the number of days requiring ventilator support. The subsequent section contained details on comorbid conditions that may have aggravated COVID-19 symptoms, including diabetes mellitus, hypertension, cardiac diseases, thyroid disorders, renal diseases, liver diseases, respiratory diseases, cancer, previous history of surgery, and pregnancy. The final section comprised the final outcome of the treatment.
**Table 1**  
Baseline characteristics of patients with SARS-CoV-2 infection, and vaccination status  

|                  | Enrolled patients(n = 569) | Vaccinated group(n = 137) | Non-vaccinated group(n = 432) | p-value |
|------------------|---------------------------|---------------------------|-------------------------------|---------|
| Age (years)      | 55.55 ± 15.769            | 61.71 ± 11.93             | 51.59 ± 16.32                 | 0.001   |
| Gender           | Male (%)                  | 347 (61%)                 | 84 (61.3%)                    | 0.505   |
|                  | Female (%)                | 222 (39%)                 | 53 (38.7%)                    |         |
| Diabetes (%)     | 149 (26.2%)               | 40 (29.2%)                | 109 (25.2%)                   | 0.373   |
| Hypertension (%) | 214 (37.6%)               | 63 (46%)                  | 151 (35%)                     | 0.026   |
| IHD (%)          | 37 (6.5%)                 | 11 (8%)                   | 26 (6%)                       | 0.427   |
| Thyroid diseases | 26 (4.6%)                 | 8 (5.8%)                  | 18 (4.2%)                     | 0.480   |
| Kidney diseases  | 26 (4.6%)                 | 2 (1.5%)                  | 24 (5.6%)                     | 0.058   |
| Liver diseases   | 3 (0.5%)                  | 1 (0.7%)                  | 2 (0.5%)                      | 0.563   |
| Respiratory diseases | 15 (2.6%) | 2 (1.5%)                  | 13 (0.3%)                     | 0.540   |
| Neoplasms        | 6 (1.1%)                  | 1 (0.7%)                  | 5 (0.7%)                      | 1.000   |

**Table 2**  
In-hospital stays and outcome differences between the two groups  

|                  | Enrolled patients(n = 569) | Vaccinated group(n = 137) | Non-vaccinated group(n = 432) | p-value |
|------------------|---------------------------|---------------------------|-------------------------------|---------|
| Length of ward stay in days | 6.11 ± 4.816             | 6.21 ± 3.20               | 5.56 ± 4.55                   | 0.257   |
| Length of hospital stay in days | 8.35 ± 6.418             | 8.53 ± 5.89               | 8.30 ± 6.58                   | 0.179   |
| Length of ICU stay in days (n) | 7.67 ± 5.32 (166)        | 4.47 ± 2.3 (21)           | 6.29 ± 2.19 (145)             | 0.001   |
| Duration of mechanical ventilation in days (n) | 4.49 ± 2.29 (128) | 3.77 ± 2.20 (9)          | 6.83 ± 2.28 (119)             | 0.001   |
| Mortality        | 99 (17%)                  | 4 (2.9%)                  | 95 (22%)                      | 0.001   |

* Mean calculated for the number of subjects admitted to the ICU, excluding those who were not.  
** Mean calculated for the number of subjects requiring mechanical ventilation, excluding those who did not.

**Statistical analysis**

Numerical variables were presented as mean ± SD. Discrete variables were summarized as percentages. The qualitative data were evaluated using Pearson’s chi-square test or Fisher’s absolute-value chi-square test, while comparisons of quantitative variables between two groups were performed using an independent-sample t-test or the Mann-Whitney test, depending on normality of data, and results with a p-value < 0.05 were considered to be statistically significant. The long-term survival for each study group was assessed using Kaplan-Meier analysis with log-rank testing. The results were expressed as hazard ratios (HR) with associated 95% confidence intervals. Cox regression analysis was used to determine variables predictive of survival. All analyses were performed using IBM SPSS Statistics, version 26.

**Results**

This was a retrospective observational study conducted at a single tertiary COVID care center in western India. Between April 1 and June 30, 2021, 569 patients were enrolled in the study, based on the eligibility criteria described previously. There were 347 males and 222 females, with a mean age of 55.55 ± 15.769 years, with a diagnosis of SARS-CoV-2 infection confirmed by RT-PCR via an oropharyngeal and nasopharyngeal swab. Among the vaccinated patients, mean ± SD age was 61.70 ± 15.7 years, while that for the non-vaccinated group was 53.59 ± 12.1 years, giving a statistically significant difference.

One hundred and sixty-nine patients had no chronic comorbidity. On the other hand, 476 patients presented one or more comorbidities (diabetes 26.2%, hypertension 37.6%, IHD 6.5%, thyroid diseases 4.6%, kidney diseases 4.6%, liver diseases 0.5%, respiratory diseases 2.6%, and neoplasms 1.1%), as shown in Table 1.

Of the 569 patients, 137 (24.08%) had been vaccinated with a single dose of ChAdOx1 nCoV-19 vaccine, while 432 (75.92%) had not received any form of vaccination. Table 2 shows the differences between the two groups regarding the lengths of stay and outcomes during the hospital stay. There were no significant differences in total hospital stay or average length of stay in a ward (p = 0.179 and 0.257, respectively). However, there were significant differences between both groups in terms of length of ICU stay (p = 0.001) and duration of mechanical ventilation (p = 0.001). Twenty-one vaccinated patients were admitted in the ICU, with a mean stay of 4.47 ± 2.3 days, while 145 patients in the non-vaccinated group were admitted to the ICU, with a mean stay of 6.29 ± 2.19 days [Figure 1]. Similarly, nine patients in the vaccinated group required mechanical ventilation, with a mean of 3.77 ± 2.20 days of support, while 119 non-vaccinated patients required mechanical ventilation, with a mean of 6.83 ± 2.28 days of support [Figure 2]. A high rate of mortality was observed in the non-vaccinated group (95/432; 22%) as compared with the vaccinated group (4/137; 2.9%), showing a significant difference (p < 0.0001). To investigate whether high differences between the groups in terms of age, gender, and comorbidities could obscure an association with prognosis in COVID-19 patients, a multimodal logistic regression analysis was performed, with mortality as the outcome. After correcting for gender, age, and comorbidities, vaccination was found to be independently associated with a lower risk of mortality (p < 0.001; HR 0.142; 95% CI 0.051–0.390). This indicated that vaccinated individuals had an additional 86% protection against mortality after a positive COVID-19 test result [Figure 3].

Of the 292 patients with systemic comorbidities, 83 (60.5%) belonged to the vaccinated group and 209 (48.3%) to the non-vaccinated group. There were significant differences in ward stays and ICU stays between the two cohorts. Vaccinated patients with comorbidities had a mean length of stay in the hospital of 8.26 ± 4.57 days, while that of non-vaccinated patients was 8.94 ± 7.16 days; this difference was not significant (p = 0.363). However, the mean length of stay in the ward was 7.65 ± 4.14 days for the vaccinated patients, compared with 5.09 ± 4.80 days for non-vaccinated patients, giving a statistically significant difference (p < 0.001). The difference in length of ICU stay was also significant (p < 0.001), with vaccinated patients staying for a mean of 3.61 ± 2.06 days and non-vaccinated patients staying for a mean 6.51 ± 2.64 days.

**Discussion**

The COVID-19 pandemic has proven to be the biggest healthcare challenge of the 21st century, especially for a developing country like India. The first wave showed that timely lockdown measures can help in curbing the spread of the disease. However, the second wave involving the mutated Delta variant has overwhelmed
the medical infrastructure, with hospitals struggling to cope with critical drugs and oxygen shortage. As of June 30, 2021, deaths had passed the 0.4 million mark, with 0.11 million in May 2021 alone [COVId-19 Dashboard, 2021]. Prior to April 1, 2021, in what can be loosely termed the first COVID-19 wave in India, little more than 0.16 million deaths had been reported [Worldometers, 2021].

The priority now is acquiring immunity, which can be either naturally or through vaccination. Given India’s status as the second-most populous country in the world, it is understandable that the people of India have varying perceptions and concerns about COVID-19 vaccines. Distribution of public health information and education about vaccines had begun before the government approval of Covishield™ and Covaxin™. It is essential that distribution of vaccines and access to vaccination occur in an equal manner countrywide, to ensure that the maximum number of the population is immunized safely and effectively.

WHO has identified vaccine hesitancy as a cause of a global health risk [MacDonald and SAGE group, 2015]. Multiple factors play a role in determining whether a newly introduced vaccine will be accepted widely or not. Aside from these, problems of production, manufacturing, marketing, cold-chain maintenance, and cost also factor into the advent of new vaccines [Sallam, 2021]. Normally it would take months to years to complete the phases of a randomized controlled clinical trial, in order to prove the safety and efficacy of a vaccine. However, with a rapidly spreading and mutating virus, it is imperative that accelerated studies and emergency approvals are implemented as soon as possible.

The aim of our study was to establish the association of partial vaccination with the ChAdOx1 nCoV-19 vaccine with various parameters, such as comorbidity, ICU requirement, length of stay, and mortality in hospitalized COVID-19 patients. Our study found that the overall hospital stay for vaccinated patients was

---

**Figure 1.** Mean ICU stay by age group, for the vaccinated and non-vaccinated groups

**Figure 2.** Mean ventilation time by age group, for the vaccinated and non-vaccinated groups
study suggests the ted can dia. the multiple had 21.9% showed recorded [similar, improved also patients. 6.21 rates cant a significantly more patients, in order to evaluate the parameters more effectively. Moreover, SARS-CoV-2 antibody levels were tested only in a very small sample of patients due to financial constraints, hence these data were not included in our analysis. Various studies have shown higher levels of SARS-CoV-2 antibodies against different antigens in patients who have received a single dose of the vaccine [Jeewandara et al., 2021; Angyal et al., 2021]. The sample size of our study was also reduced due to study site limitations. A multicentric study could have provided a much larger sample size.

Conclusion

A single dose of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) was shown to be highly effective, with a pivotal role in reducing ICU stay, ventilator usage, and mortality, even at the peak of the COVID-19 pandemic. Safe vaccination is an effective and necessary measure to curb Delta variant or any other COVID-19 variant spread. In countries like India, a complete and early rollout of mass vaccination programs is the key to success in managing the COVID-19 pandemic. Our results are an encouraging indication of the power and promise of vaccines against COVID-19, especially ChAdOx1 nCoV-19.

Acknowledgements

The authors would like to acknowledge Dr Dileep Mavalankar, Director and Dr Komal Shah, Assistant Professor, Indian Institute of Public Health, Gandhinagar, Gujarat, India for their expertise.
Conflicts of interest

None

References

Angyal A, Longet S, Moore S, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2 infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. Available at SSRN: https://ssrn.com/abstract=3812375 or 10.2139/ssrn.3812375

Asrani P, Eapen MS, Hassan SS, Sohal SS. Implications of the second wave of COVID-19 in India. The Lancet Respiratory Medicine 2021 Jun 30.

Bagchi S. The world's largest COVID-19 vaccination campaign. The Lancet Infectious Diseases 2021;21(3):323.

Bhattacharya A, June 11, 2021. COVID-19: deaths in 2nd wave cross 2 lakh at daily average of over 2000. The Times of India. https://timesofindia.indiatimes.com/india/covid-19-deaths-in-2nd-wave-cross-2-lakh-at-daily-average-of-over-2000/articleshow/83414459.cms

COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed on July 26, 2021.

Dagan N, Bara N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipshitz M, Reis B, Balicer RD. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine 2021;384(15):1412–23.

Ellia R, Reddy S, Jogiand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious Diseases 2021 Mar 8.

Ellia R, Vadrevu KM, Jogdand H, Prasad SD, Reddy S, Sarangi V, et al. Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial. 10.1016/S1473-3099(20)30942-7 (2021).

Government of India COVID-19 dashboard. https://www.mygov.in/covid19 (Accessed July 6, 2021)

India: WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/region/searo/country/in (accessed July 1, 2021)

(Recovery or Death) in India — Coronavirus Cases — Worldometer. https://www.worldometers.info/coronavirus/country/india (accessed July 1, 2021)

Jain V, Iyengar KP, Vaishya R. Differences between first wave and second wave of COVID-19 in India. Diabetes Metab Syndr 2021;15:1047–8.

Jeewandara C, Kamaladasa A, Pushpakumara PD, Jayathilaka D, Abetharana IS, Danasekara DR, et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nature Communications 2021;12(1):1–9.

Kale P, Gupta E, Bihari C, Patel N, Rooge S, Pandy A, et al. Clinicogenomic analysis of breakthrough infections by SARS-CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. medRxiv 2021, Jan 1.

Lancet T. India’s COVID-19 emergency. Lancet 2021;397(10286):1683.

MacDonald NE. Working SAGE. Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine 2015;13:4186–4.

Ministry of Home Affairs (2021). Guidelines for effective control of COVID-19. https://www.mha.gov.in/sites/default/files/MHADirector_23032021.pdf

Pujari BS and Shekatkar SM. Multi-city modelling of epidemics using spatial networks: Application to 2019-nCoV (COVID-19) coronavirus in India. medRxiv 2020. doi: 10.1016/j.jcvi.2020.03.13.2003386

Ramakrishnan M, Subharayan P. Impact of vaccination in reducing hospital expenses, mortality and average length of stay among COVID-19 patients. A retrospective cohort study from India. medRxiv 2021, Jan 1.

Ranjan R, Sharma A, Verma MK. Characterization of the second wave of COVID-19 in India. medRxiv 2021, Jan 1.

Sadoff J, Gray G, Vandeboch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. New England Journal of Medicine 2021;384(23):2187–201.

Sallam M. COVID-19 vaccine hesitancy worldwide — a concise systematic review of vaccine acceptance rates. Vaccines 2021;9(2):160. doi:10.3390/vaccines9020160.

Singh R and Adhikari R. 2020. Age-structured impact of social distancing on the COVID-19 epidemic in India. arXiv 2003;12055.

Swift MD, Creeher LE, Tande AJ, Tommasio CP, Hainy CM, Chu H, Murad MH, Berbari EF, Vrk A. Effectiveness of mRNA COVID-19 vaccines against SARS–CoV–2 infection in a cohort of healthcare personnel. Clinical Infectious Diseases 2021 Apr 26.

Thagarajan K. Why is India having a COVID-19 surge? BMJ 2021;373:n1124.

Tyagi K, Ghosh A, Nair D, Dutta K, Bhandari PS, Ansari IA, Misra A. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetologia & Metabolic Syndrome. Clinical Research and Reviews 2021;15(3):1067–8.

Vaccine information, ICMR New Delhi. COVID-19 vaccine. (accessed July 17, 2021).

Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Reggs J, Bradley D, Chuter A, De Lusignan S. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet 2021;397(10285):1646–57.

Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021;397(10260):95–111.

Weekly epidemiological update on COVID-19 — 29 June 2021, Edition 46: Emergent situational updates.

World Health Organization, Director General’s opening remarks. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 (accessed July 15, 2021).

International Journal of Infectious Diseases 113 (2021) 282–287